{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:11:58Z","timestamp":1760148718102,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ricerca Corrente"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Patients with atopic\/allergic disorders, including atopic dermatitis (AD), allergic rhino-conjunctivitis (AR), chronic rhinosinusitis with\/without nasal polyps (CRSwNP\/CRSsNP), bronchial asthma, food allergy, and eosinophilic esophagitis (EoE), often share a common genetic background, a type Th2 polarized immune response, and several environmental factors [...]<\/jats:p>","DOI":"10.3390\/jpm13060941","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T02:41:35Z","timestamp":1685673695000},"page":"941","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Multidisciplinary Approach for Type 2 Allergic Diseases: What Do Biologics Teach Us?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-9921","authenticated-orcid":false,"given":"Mauro","family":"Maniscalco","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, 80138 Naples, Italy"},{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Detoraki","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Federico II University, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1134","authenticated-orcid":false,"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nolano","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amato","family":"De Paulis","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Federico II University, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Federico II University, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-2033","authenticated-orcid":false,"given":"Elena","family":"Cantone","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/cea.14029","article-title":"Type 2 immunity-driven diseases: Towards a multidisciplinary approach","volume":"51","author":"Hassoun","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1111\/all.15445","article-title":"A pathogenic integrated view explaining the different endotypes of asthma and allergic disorders","volume":"77","author":"Maggi","year":"2022","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","article-title":"Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis","volume":"12","author":"Haddad","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2008.00713.x","article-title":"Welcome to the neighborhood: Epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites","volume":"226","author":"Saenz","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-immunol-051116-052350","article-title":"Th2 Cells in Health and Disease","volume":"35","author":"Nakayama","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40413-018-0192-5","article-title":"Type 2 immunity in asthma","volume":"11","author":"Caminati","year":"2018","journal-title":"World Allergy Organ. J."},{"key":"ref_7","first-page":"e2021525","article-title":"Atopic dermatitis and atopic march: Which link?","volume":"92","author":"Maiello","year":"2021","journal-title":"Acta Biomed."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"889221","DOI":"10.3389\/falgy.2022.889221","article-title":"White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA","volume":"3","author":"Raap","year":"2022","journal-title":"Front. Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.amjoto.2010.07.013","article-title":"Chronic rhinosinusitis in the setting of other chronic inflammatory diseases","volume":"32","author":"Chandra","year":"2011","journal-title":"Am. J. Otolaryngol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000357010","article-title":"Eosinophilic esophagitis: Asthma of the esophagus?","volume":"32","author":"Virchow","year":"2014","journal-title":"Dig. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.2147\/JIR.S311640","article-title":"Insights into the Implications of Coexisting Type 2 Inflammatory Diseases","volume":"14","author":"McCormick","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/alr.22808","article-title":"A multicenter real-life study on the multiple reasons for uncontrolled allergic rhinitis","volume":"11","author":"Cools","year":"2021","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13601-020-00332-z","article-title":"Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma","volume":"10","author":"Wang","year":"2020","journal-title":"Clin. Transl. Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.alit.2016.04.011","article-title":"Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine","volume":"65","author":"Agache","year":"2016","journal-title":"Allergol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.anai.2019.12.011","article-title":"Phenotypes and endotypes in eosinophilic esophagitis","volume":"124","author":"Ruffner","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.02.004","article-title":"Molecular and cellular mechanisms of food allergy and food tolerance","volume":"137","author":"Chinthrajah","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaci.2021.02.019","article-title":"Optimal human pathogenic TH2 cell effector function requires local epithelial cytokine signaling","volume":"148","author":"Calise","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaci.2015.08.007","article-title":"Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T(H)2 cell subpopulation with enhanced function","volume":"137","author":"Yin","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fimmu.2019.00570","article-title":"Immune Cell-Epithelial\/Mesenchymal Interaction Contributing to Allergic Airway Inflammation Associated Pathology","volume":"10","author":"Hirahara","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"945063","DOI":"10.3389\/fimmu.2022.945063","article-title":"Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis","volume":"13","author":"Kokubo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin. Exp. Allergy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults with Active Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1002\/cti2.1433","article-title":"Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2023","journal-title":"Clin. Transl. Immunol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/6\/941\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:04Z","timestamp":1760125624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/6\/941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jpm13060941"],"URL":"https:\/\/doi.org\/10.3390\/jpm13060941","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}